small nuclear ribonucleoprotein polypeptide F pseudogene 4Genealiases: []
Q-omics provides the consensus-scored SNRPFP4 profile across patient tissues and cancer cell-line models. SNRPFP4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNRPFP4 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, SNRPFP4 RNA expression shows 13,053 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where SNRPFP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPFP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPFP4 survival associations across molecular data types. SNRPFP4 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPFP4 RNA expression–survival associations across cancer types. High SNRPFP4 expression shows unfavorable associations in KIRC, KICH, ACC, LIHC and PAAD, but favorable associations in READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNRPFP4 RNA expression.
This table summarizes SNRPFP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNRPFP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPFP4 shows higher tumor expression in LUAD, HNSC, LUSC, BLCA, BRCA and COAD. The LUAD box plot shows higher SNRPFP4 RNA expression in tumor versus normal tissue (log2 FC = +0.197, t-test p < 0.001).
This table shows molecular features associated with SNRPFP4 in patient tissues and cancer cell lines. In patient samples, SNRPFP4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
